August 22, 2018
The First Comprehensive Clinic in Illinois Providing Support for Individuals with Angelman Syndrome (CHICAGO) – Rush University Medical Center and the Angelman Syndrome Foundation (ASF), a national nonprofit organization headquartered in Aurora, Ill., announced the official opening of the Angelman […]
Read more
August 6, 2018
— OV101 achieved primary endpoint of safety and tolerability — — Robust and statistically significant improvement (p=0.0006) in the first prespecified efficacy endpoint(CGI-I) observed at 12 weeks of treatment in once-daily dose group compared to placebo — — STARS data […]
Read more
June 19, 2018
Availability of Dedicated Code Will Advance Research and Development of Treatments for this Unique, Well-defined Syndrome and Lead to Improved Clinical Care Nashville, TN, June 19, 2018 — The Angelman Biomarkers and Outcome Measures (A-BOM) Alliance today announced that the […]
Read more
October 16, 2017
Congratulations to Dr. Arthur Beaudet on being named the 2017 recipient of the Victor A. McKusick Leadership Award from the American Society of Human Genetics. Dr. Beaudet has been a pioneering force in Angelman syndrome research; it’s truly because of […]
Read more
September 18, 2017
The Angelman Syndrome Foundation is issuing the following statement regarding healthcare legislation in the US because of its impacts on the lives of people with Angelman syndrome and their families. Statement from Angelman Syndrome Foundation Board of Directors: The healthcare […]
Read more
August 14, 2017
See the paper by Matthew Judson in The Journal of Neuroscience. Summary Many individuals with Angelman syndrome (AS) have microcephaly—a smaller head and brain size—than typically developing individuals. This microcephaly is not present at birth, but becomes evident sometime during the […]
Read more
June 22, 2017
Angelman Biomarkers and Outcome Measures Alliance and Roche begin patient-centered qualitative research to inform potential outcome measures for Angelman syndrome clinical trials Nashville, Tenn. (June 22, 2017) – A collaborative group of parent-driven organizations seeking a cure for Angelman syndrome has […]
Read more
May 11, 2017
ASF-funded Research Identifies Biomarker for Clinical Trials ASF-funded research published in the Journal of Neurodevelopmental Disorders has identified that delta—a frequency of brain rhythms identifiable by EEG scans—can serve as a reliable biomarker for pre-clinical and clinical trials in Angelman syndrome. The research team, […]
Read more